Fifty-four patients were enrolled in the study and received study treatment (from six centres in Brazil, one in Chile, two in Colombia, two in Mexico and one in Panama). Appropriate patient selection for candidaemia studies remains challenging due to issues associated with early identification of infection and a variety of concomitant risk factors; insufficient enrolment to this study meant that the target of 210 patients was not achieved. Patient disposition is shown in Fig. 1. In total, the per protocol population (all MITT

subjects who were compliant with the study protocol) comprised 22 (40.7%) patients and 32 (59.3%) patients discontinued the study prematurely; the most common reason for discontinuation was death (n = 23, 42.6%), followed by lack of efficacy (n = 4, 7.4%), other reasons (n = 3, 5.6%), AEs (n = 2, 3.7%), lost to follow-up, and no longer willing to participate (both n = 1, 1.9%). Other reasons included a legal representative

www.selleckchem.com/products/Temsirolimus.html withdrawing informed consent, voriconazole being added to treatment due to isolation of moulds and yeast in blood culture, and doctors and relatives not accepting continuation of treatment due to diagnosis of brain death. Forty-four patients were included in the MITT population and the overall median duration of therapy with IV anidulafungin was 9.5 days (range 2–25 days). Ten patients were excluded from the MITT population because they did not selleck chemicals llc have a positive baseline culture for Candida within 96 h before study entry. Patient demographics and baseline characteristics of the MITT population are included in Table 1. All patients enrolled in this study were in the ICU. At study entry, 72.7% many (33/44) of patients in the MITT had been in the ICU for ≥4 days; among these patients, the overall median duration of ICU stay was 16.0 (95% CI: 8.0, 29.0) days. Within the MITT population, 14 patients were able to step-down to oral voriconazole. These patients had a shorter median duration of treatment with IV anidulafungin

(6 days), compared with that of patients who did not step-down to oral therapy (14 days). Patients who stepped-down to oral voriconazole had lower APACHE II scores and lower incidences of solid tumours and prior abdominal surgery compared with patients who remained on IV anidulafungin (Table 1). Global, clinical and microbiological response rates for the MITT population are summarised in Table 2. The primary endpoint of global response rate at EOT for the MITT population was 59.1% (95% CI: 44.6, 73.6), when 13 patients with missing responses were counted as failures. Patients with an indeterminate or missing response could not be assessed for clinical or global response at the EOT because they either received less than three doses of anidulafungin or they died of a cause other than candidaemia before the planned EOT. At day 30, the all-cause mortality rate in the MITT population was 43.